1. The use of β-blockers after myocardial infarction: no doubts remain. Nature Reviews Cardiology, 2026
  2. Sekundærforebygging med betablokkere etter hjerteinfarkt. Tidsskrift for Den norske legeforening, 2026. (Kronikk)
  3. Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score. European Journal of Preventive Cardiology (EJPC), 2026.
  4. Cardiac-related symptoms in individuals ≥65 years without diagnosed cardiac disease: insights from the NORSCREEN-trial. European Heart Journal Open, 2026.
  5. Beta-Blockers after Myocardial Infarction. Reply. The New England Journal of Medicine, 2026, page 824-825.
  6. Individual lifetime cardiovascular disease risk and preventive treatment benefit in patients with established atherosclerotic cardiovascular disease: Development and geographic recalibration of the SMART-REACH2 model. European Heart Journal, 2026. (The link to this article will be provided shortly)
  7. Clinical and psychosocial factors predicting persistent smoking in hospitalized patients with atherosclerotic vascular disease: A prespecified analysis of two randomized controlled trials. Tobacco Prevention & Cessation, 2026.
  8. Skal vi fortsatt gi betablokker etter hjerteinfarkt? Hjerteforum N° 1 / 2026 / vol 39, s. 86.
  9. Bata-Blocker therapy after myocardial infraction in patients with preserved left ventricular ejection fraction: An individual patient data meta-analysis of randomized controlled trials. Hjerteforum N° 1 / 2026 / vol 39, s. 120.
  10. Validating National Registry Data for Randomised Trials: Comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial. European Heart Journal – Quality of Care and Clinical Outcomes, 2026
  11. Cost-effectiveness of in-hospital motivational smoking cessation counselling and proactive referral to community-based follow-up. Addiction, 2026.
  12. Beta-blockers, depression, and anxiety after myocardial infarction: the BETAMI-DANBLOCK trial. European Heart Journal, 2026.
  13. Individually Tailored monitoring at home after hospitalization for HEART failure (IT-HEART): Design and baseline characteristics of a randomized clinical trial. Heart Failure Reviews, 2026.
  14. Patient- and healthcare system predictors of participation in a municipal smoking cessation programme after hospitalisation for atherosclerotic cardiovascular disease. V Getz (presenter), K Pleym, T Dammen, E Husebye, E Sverre1, Peersen, C Papageorgiou, H Weedon-Fekjær, and J Munkhaugen. Poster presentation, ESC Preventive Cardiology Congress 2026, Ljubljana, Slovenia.
  15. Cost-effectiveness of in-hospital motivational smoking cessation counselling and proactive referral to community-based follow-up. Karin Pleym (presenter), Ingrid Engebretsen, Elise Sverre, Toril Dammen, Einar Huseby, Mohpal Singh Kahlon, Marie Stugaard, Henrik Støvring, Ivar Sønbø Kristiansen, and John Munkhaugen. Poster presentation/conference abstract, ESC Preventive Cardiology Congress 2026, Ljubljana, Slovenia.
  16. Effect of the ugt1a3*2 haplotype on pharmacokinetics and pharmacodynamics of atorvastatin in patients with coronary heart disease. AS Uduma (presenter) , E Sverre , J Munkhaugen , AC Svarstad , SS Tuv , NT Vethe. Poster presentation/conference abstract, ESC Preventive Cardiology Congress 2026, Ljubljana, Slovenia.
  17. Effect of long-term beta-blocker therapy on physical activity after myocardial infarction: a post hoc analysis of the BETAMI trial. E Sverre (presenter), EM Madssen, AMD Kristensen , JE Nyen, A Bakken, T Holmager, J Jortveit, T Edvardsen, T Steigen , D Atar, R Wiseth, J Munkhaugen. Poster presentation/conference abstract, ESC Preventive Cardiology Congress 2026, Ljubljana, Slovenia.
  18. Beta-blocker therapy and sleep disturbances after myocardial infarction: a prespecified sub-study of the BETAMI-DANBLOCK trial. J Nyen (presenter) , AMD Kristensen , MW Fagerland , T Dammen , AD Zwisler , MH Olsen , M Maeng, S Halvorsen, K Vikenes, A Bakken, TLF Holmager, D Atar, E Prescott, J Munkhaugen. Poster presentation/conference abstract, ESC Preventive Cardiology Congress 2026, Ljubljana, Slovenia.
  19. Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.  European Heart Journal, 2026
  20. Temporal trends in the primary prevention of implantable cardioverter-defibrillator selection and long-term outcomes in patients with non-ischaemic dilated cardiomyopathy and ischaemic cardiomyopathy, EP Europace, 2026.
  21. Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model. European Heart Journal, 2026
  22. Effect of the ugt1a3*2 haplotype on pharmacokinetics and pharmacodynamics of atorvastatin in patients with coronary heart disease. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  23. Beta-blocker therapy and angina pectoris after myocardial infarction: a BETAMI-DANBLOCK substudy. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  24. Cost-effectiveness of in-hospital motivational smoking cessation counselling and proactive referral to community-based follow-up. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  25. Validating national registry data for randomised trials: comparison of adjudicated and registry-derived cardiovascular outcomes in the BETAMI-DANBLOCK trial. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  26. Beta-blocker therapy and sleep disturbances after myocardial infarction: a prespecified sub-study of the BETAMI-DANBLOCK trial. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  27. Risk stratified effect of beta-blockers after myocardial infarction in patients without heart failure: A substudy of the BETAMI-DANBLOCK trial. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  28. Individually Tailored monitoring at home after hospitalization for HEART failure (IT-HEART): Design and baseline characteristics of a randomized clinical trial.European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  29. Effect of long-term beta-blocker therapy on physical activity after myocardial infarction: a post hoc analysis of the BETAMI trial. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  30. Patient- and healthcare system predictors of participation in a municipal smoking cessation programme after hospitalisation for atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology (EJPC) supplement, 2026. Conference abstract.
  31. Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial. European Journal of Preventive Cardiology, 2026.
  32. Contemporary post-discharge management in heart failure at home (STRONG@HOME), European Journal of Heart Failure, Issue Supplement_2, June 2026
  33. Artificial intelligence-enabled electrocardiographic detection of acute occlusive myocardial infarction. Research Square. (preprint)
  34. Risk and outcomes of adrenal crisis in primary adrenal insufficiency: Evidence from a 24-year nationwide cohort study. J Intern Med. 2026
  35. Betablokkerbehandling etter hjerteinfarkt? Oppdatert kunnskapsgrunnlag etter nyere studier. Norsk indremedisinsk forening. Fagtidskrift Indremedisineren, 2026 (2) (s.32-35).